Synlogic announced that the European Medicines Agency issued a positive opinion on the company’s application for orphan designation for SYNB1934 for the treatment of phenylketonuria. "We are pleased that the EMA has issued a positive opinion for orphan designation for SYNB1934, in recognition of the urgent need for new treatment options for people living with this devastating disease," said Aoife Brennan, M.B. Ch.B., Synlogic President and CEO. "This designation also comes at a pivotal time as we prepare to begin our Phase 3 trial for PKU in the first half of this year."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SYBX:
- Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
- Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
- Synlogic Announces Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
- Synlogic To Present Three Data Presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting